ONO-1110 misses endpoints in three pain trials; Ono still plans further research
After the primary endpoints were missed, subgroup and exploratory analyses offered leads for further research. Ono will focus ONO-1110 development on three pain conditions, while research in depression and social anxiety disorder will stop.